This article explores pervasive corruption within the pharmaceutical industry, highlighting how promising alternative treatments, such as ivermectin and chlorine dioxide, are deliberately suppressed. It delves into the systemic protection of corporate profits over public health, revealing a troubling reality.
The author candidly admits to long acknowledging corruption in various sectors, including big pharma. Initially, this awareness was somewhat detached, a conceptual understanding of inflated contracts, highly profitable deals, and unfair price markups on essential medicines. These issues were seen as distant economic problems, not direct threats to individual well-being or the integrity of scientific discovery, largely remaining in the realm of abstract financial malpractice rather than concrete health impacts.
Acknowledging the occasional low-quality batch or production flaw as an inherent risk in any profit-driven manufacturing process, the writer's perspective evolved significantly. The true nature of the problem shifted from mere product inconsistencies to the active suppression of viable alternative treatments. This realization dawned when confronting instances where genuinely promising options were not just ignored but actively undermined and hidden from public and medical discourse, solely to protect existing market shares and revenue streams.
This alarming pattern became starkly evident with treatments such as ivermectin and chlorine dioxide. Instead of undergoing proper, unbiased evaluation, these alternatives faced systematic campaigns to discredit them, often fueled by commercial interests. Large pharmaceutical corporations actively worked to bury these competing options, ensuring their proprietary products maintained market dominance and continued generating immense profits. This ongoing suppression reveals the profound depth of systemic issues undermining true health care and public trust today.
Original Author: Filipe Rafaeli | Source: Brownstone Institute
Comments